You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Therapy for gastrointestinal disorders

    SBC: AGENNIX, INC.            Topic: N/A

    DESCRIPTION (Applicant's Abstract): The overall goal of this research proposal is to determine the effectiveness of recombinant human lactoferrin (rhLF) for treating gastrointestinal (GI) disorders. This Phase II proposal will focus on the ability of rhLF to treat the 01 side effects of non-steroidal anti-inflammatory drugs (NSAIDs), a class of drugs widely-us ...

    STTR Phase II 2001 Department of Health and Human ServicesNational Institutes of Health
  2. Drug Delivery System for Superficial Mycoses

    SBC: Biomedical Development Corporation            Topic: N/A

    DESCRIPTION (Provided by the applicant): The goal of this project is to establish the safety and efficacy of a unique drug delivery system for use as a sustained-release, antifungal skin preparation for the treatment of superficial mycoses. The lifetime risk of acquiring a superficial mycotic infection is estimated to be between 10 and 20 percent. In the U.S., annu ...

    STTR Phase II 2001 Department of Health and Human ServicesNational Institutes of Health
  3. DEVELOPMENT OF POLY-L-GLUTAMIC ACID PACLITAXEL CONJUGATE

    SBC: FEM CADET            Topic: N/A

    Chemoradiation improves survival for patients with locally advanced non-small cell lung cancer (NSCLC) over radiotherapy (R) alone. Les than 20% of patients have complete pathologic response to combination therapy. Paclitaxel (TXL) is effective as an anti-tumor agent and a radiosensitizer. Peripheral neurotoxicity and granulocytopenia limit its dosage; acute effects from TXL's infusion include na ...

    STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  4. VALIDATION OF TRANSILLUMINATION AND THE NEVOSCOPE

    SBC: TRANSLITE            Topic: N/A

    DESCRIPTION (provided by applicant): Skin cancer is the most common of all cancers and melanoma is a deadly skin cancer that accounts for over 75% of all the skin cancer deaths in the United States. The incidence of melanoma is rising at approximately 3% per year. Early detection of melanoma results in 95% cure rate. But, early detection of melanoma is difficult because of the subtle changes that ...

    STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  5. Gene Therapy for Human Malignant Melanoma

    SBC: Introgen Therapeutics, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Melanoma is the most malignant of skin cancers. In the USA, the incidence of melanoma is increasing more rapidly than any other cancer. Melanoma is the most frequently occurring cancer in women from the ages of 25-30, and has recently replaced leukemia as responsible for the most lost work hours in the United States. Currently there is no approved therapy tha ...

    STTR Phase II 2003 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a Peptide Microchip System

    SBC: ATACTIC TECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The purpose of this proposal is to develop a protein assay technology that will parallel the newly developing oligonucleotide microarray techniques. We will develop a peptide system capable of performing high throughput real time measurements in parallel on a microfluidic chip. We will develop the chemistry to prepare these chips in Phase I and develop the s ...

    STTR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
  7. Novel CSF biomarker to predict impaired cognition in HIV

    SBC: INFLAME THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The focus of this project is to explore the relationship between inflammatory cells and cognitive dysfunction in populations with HIV-1 infection. Extensive work has found that a biomarker is detected in lumbar cerebrospinal fluid of HIV(+) subjects with impaired cognition. Presently there are no suitable clinical tests to identify early neuro-inflammatory inju ...

    STTR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
  8. Mandibular Bone transport Reconstruction Plate

    SBC: Custom Scientific            Topic: N/A

    DESCRIPTION (provided by applicant): Surgical excision of hard and soft tissues of the head and neck or high impact trauma can lead to lead to major tissue deficits. Reconstruction of the lower jaw typically involves bone, gingiva, and teeth. Current mandibular distraction devices are used in combination with reconstruction plates, but while the reconstruction plates take the contour of the jaw, t ...

    STTR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a transgenic rat to study brain aging

    SBC: INFLAME THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Neuro-inflammation is thought to be an important factor in age-dependent loss of neuron associated with Alzheimer's disease. We seek STTR funding to develop a unique transgenic rat that serves as a model for chronic neuro-inflammation and age-dependent loss of neurons. Presently, no other animal model offers specific patterns of neuro-inflammation, presence of ...

    STTR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  10. Lactoferrin as an Adjuvant for Cellular Immunity

    SBC: Pharmareview Corporation            Topic: N/A

    The Specific Aims of the proposal will be modified to reflect a change in scope, according to recommendations from the review panel. Specifically, the revised scope of the project will now only include AIM I and AIM II of the proposal. There will be no change in scope to the first two aims. All experiments proposed in AIMs I and II can be accelerated to meet the two year time commitment. Regarding ...

    STTR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government